Galien week of innovation

Product: Aprocitentan

Company: Idorsia Pharmaceuticals Ltd. 

About the Product:

TRYVIO (aprocitentan) is the first and only hypertension therapy to target the endothelin pathway, a fundamental, but previously unaddressed driver of disease onset, progression, and complications. Hypertension affects ~120 million US adults, with ~26 million uncontrolled hypertension, facing up to 95% higher risk of cardiovascular events. In clinical and real-world studies, TRYVIO delivered rapid, durable, double-digit blood pressure reductions with an excellent safety profile, including in difficult-to-treat populations, like Black, elderly, postmenopausal women, obese, and patients with CKD, type-2 diabetes, or heart failure. With FDA approval, guideline inclusion, and blockbuster potential in a growing global market, TRYVIO is positioned to transform treatment of difficult-to-control hypertension.v

Product: Xacduro 

Company: Innoviva Specialty Therapeutics, Inc. 

About the Product:

XACDURO® is the first pathogen-targeted antibacterial developed and approved to treat hospital acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii. Previously, there was no clear standard of care antibiotic regimen for Acinetobacter infections resulting in a mortality rate ranging from 30-70%. The approval of XACDURO addresses a global public health threat and delivers a safe and effective treatment option for patients suffering from these serious and life-threatening infections.

Product: Zevtera 

Company: Innoviva Specialty Therapeutics, Inc. 

About the Product:

ZEVTERA® is an advanced-generation cephalosporin antibiotic uniquely developed to treat resistant bacterial infections especially methicillin resistant staphylococcus aureus (MRSA) bacteremia. The innovative and tenacious global development program spanned several companies and culminated in FDA approval for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis. The approval for this life-threatening indication represented the first for an antibiotic in almost 20 years.

Product: Pluvicto  

Company: Novartis

About the Product:

Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapy (RLT) approved in the US and EU for a type of advanced prostate cancer. RLTs are medicines that combine the precision of targeted therapies with the power of radioactive medicine. A targeting compound, or ligand, links with a radioactive isotope to deliver radiation therapy directly to cancer cells, with the goal of limiting impact on nearby healthy cells. Novartis is pioneering the development of multiple assets on the RLT platform, with the aim of bringing potential new treatment options for various types of cancer.

Product: ZAVZPRET™ 

Company: Pfizer Inc.

About the Product:

ZAVZPRET™ (zavegepant) was developed to address unmet needs in migraine treatment, especially for patients not well served by oral triptans or CGRP antagonists. Approved in the U.S. in 2023, it expands the therapeutic toolbox with a unique, non-oral CGRP antagonist. ZAVZPRET™ offers robust efficacy, good tolerability, and a convenient unit-dose nasal spray for acute treatment. Its ease of use and effectiveness support most migraine treatment goals. As the only available non-oral option in its class, it enables individualized care, helping patients minimize functional disability and return to normal activities with a treatment tailored to their needs and preferences.

Product: VOQUEZNA

Company: Phathom Pharmaceuticals

About the Product:

VOQUEZNA (vonoprazan) is a first-in-class potassium-competitive acid blocker (PCAB) approved in the U.S. for the treatment of gastroesophageal reflux disease (GERD) and, in combination with antibiotics, for H. pylori infection. With a novel mechanism of action, VOQUEZNA delivers rapid, potent, and durable acid suppression, with a safety profile comparable to proton pump inhibitors (PPIs). In pivotal Phase 3 trials, VOQUEZNA demonstrated key efficacy advantages over a PPI across multiple endpoints. Its approval represents the first major innovation in GERD treatment in more than 30 years, offering the potential to significantly advance care for millions of patients with acid-related disorders.